CHOP-based chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) has been the standard of care for canine B-cell lymphoma for over 3 decades. The purpose of this study was to investigate whether CHOP combined with low-dose rate half-body radiation therapy (LDRHBI) might lead to improved outcomes for dogs with this disease. Between July 1, 2013 and February 15, 2017 at VCA Western Veterinary Specialist Centre in Calgary, Canada, CHOP-LDRHBI was offered for all dogs with B-cell lymphoma as a potentially superior therapy to CHOP alone. Standardized staging diagnostics were performed in all cases including screening bloodwork, urinalysis, thoracic and abdominal imaging, bone marrow aspiration cytology and incisional lymph node biopsy.A 15-treatment, 25-week CHOP-based protocol incorporating L-asparaginase was used. LDRHBI was inserted at weeks 6 (cranial half) and 8 (caudal half); 700 cGy were delivered using a low dose rate, extended treatment distance protocol that delivered approximately 35-40 monitor units/minute. Treatment delays, chemotherapy drug dose reductions, and choice of concomitant medications were made at the discretion of the attending medical oncologist (GEM). NCSS v. 12.0.4 Statistical Software was used for all statistical analyses.
展开▼
